Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
NCT03453619
Autoimmune Diseases, C3 Glomerulonephritis
Stanford, California, United States
View Trial DetailsNCT Number: NCT02493101
The purpose of this study is to determine the location of periostin and urine periostin level in patients with lupus nephritis and IgA nephropathy.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Total of 50 lupus nephritis and IgA nephropathy patients who met the inclusion criteria were included in this study. The information sheet and informed consent will be obtained before collecting the patient's data. All patients were interviewed for collecting demographic data and laboratory testing were reviewed from patient's record. Kidney tissue and urine sample were collected at the biopsy date from patients.Kidney tissue were stained with hematoxylin and eosin (H&E), Masson's trichrome solution and immunohistochemistry for periostin. The location of periostin staining in kidney tissue were assessed by renal pathologist.
The total of 50 urine samples from patients and 50 urine samples from healthy controls were measured for periostin level by enzyme-linked immunosorbent assay. The Mann-Whitney rank-sum test was used for comparing urine periostin level between patients and healthy controls and also other variables between patients with urine periostin detection and without urine periostin detection. Spearman correlation coefficients were used test correlations between urine periostin level in patients and other variables. Receiver operating characteristic curves was generated to calculate the area under the curve and find the best cutoff value of urine periostin level for distinguishing patients from healthy controls. P-values < 0.05 were considered statistically significant.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Chulalongkorn University
Other
Potential of Periostin as a Tissue and Urinary Biomarker in Lupus Nephritis and IgA Nephropathy Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03453619
Autoimmune Diseases, C3 Glomerulonephritis
Stanford, California, United States
View Trial DetailsNCT03929887
Autoimmune Diseases, Connective Tissue Diseases
Chuncheon, South Korea
View Trial DetailsNCT05732402
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phoenix, Arizona, United States
View Trial DetailsNCT01802034
Autoimmune Diseases, Chronic Disease
New York, United States
View Trial Details